Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Helius appoints world leader in medical cannabis R&D

Media Release

Helius Therapeutics

Friday, 12 April 2019

Dr James Polston has been announced as Scientific Director at Helius Therapeutics, leaving the United States where he was a leader of research and development at the world’s largest medicinal cannabis company, by revenue.

Leading both extraction and processing during his tenure at Trulieve Cannabis Corporation, Dr Polston was responsible for major R&D initiatives, extraction, manufacturing, product development, and external scientific research programmes. He’s been directly involved in the formulation of many medicinal cannabis products on the market today in California, Oregon and Florida.

Dr Polston obtained a PhD in Biomedical Sciences from Albany Medical College, where he studied in the Department of Neuroscience and Experimental Therapeutics. He also holds an advanced degree in Biomedical Ethics from the Alden March Bioethics Institute.

Helius Therapeutics Executive Director, Paul Manning, says as New Zealand’s foremost biotech company working in medicinal cannabis R&D, Dr Polston will not only be a significant asset for Helius, but also for the country.

“James is a ground-breaking hire for Helius, and he brings extraordinary scientific expertise to our local cannabis industry. We believe New Zealand will become a centre of research excellence in this space.

“He is the first world-class medical cannabis researcher to now call New Zealand ‘home’. Dr Polston led a team of research scientists and worked extensively on product development as a senior manager at Trulieve, which has over 1,300 staff based in Florida. He brings considerable global experience building and managing cannabis laboratories and production facilities,” says Mr Manning.

Helius is New Zealand’s largest licensed medicinal cannabis company and the first certified New Zealand Grown cannabis producer. Mr Manning says securing this appointment is another example of the company’s commitment to developing novel cannabis medicines that will ease the suffering of thousands of New Zealanders.

After completing postdoctoral training at the Pennsylvania State College of Medicine, Dr Polston established Emerald Coast Research. He published work with the Director of the National Institute on Drug Abuse, has extensive clinical research experience, and is widely regarded as an expert in plant-based therapeutics after spending more than a decade investigating treatments.

Dr Polston says he started Emerald Coast Research due to the lack of testing and R&D in medicinal cannabis when the industry got started in the United States. He then moved into therapeutics production and consulting in the California cannabis industry, and eventually landed a position with Massachusetts-based Curaleaf, one of the largest vertically integrated cannabis companies in the United States. At Curaleaf, Dr Polston oversaw the buildout and management of its Oregon laboratories, formulated core products, and managed manufacturing and production.

“I started out during the pioneering years of the medicinal cannabis industry in North America. Since then I’ve had exposure to many different cannabis laboratories, giving me great insight into cutting-edge cannabis extraction technologies and techniques that are moving the industry forward today.

“I was inspired to join Helius because of its entrepreneurial energy, its strong focus on biomedical R&D, particularly its commitment to exploring and developing cannabinoids as medicine, and the opportunity to create new products that will truly help people.

“I love being part of the global evolution of medicinal cannabis, both commercially and scientifically. Helius is a business that’s genuinely looking to solve big health problems, and the New Zealand industry is in a very exciting phase,” says Dr Polston.

Dr James Polston’s appointment as Scientific Director follows news that senior pharmaceuticals industry leader Mitch Cuevas has also joined the Helius team as a Director and Senior Advisor.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Reserve Bank: Further Easing In Monetary Policy Delivered

Tēnā koutou katoa, welcome all. The Monetary Policy Committee agreed to expand the Large Scale Asset Purchase (LSAP) programme up to $100 billion so as to further lower retail interest rates in order to achieve its remit. The eligible assets remain ... More>>

Retail: Post-Lockdown Retail Card Spending Picks Up

The rise in retail card spending was boosted by sales of furniture, hardware, and appliances, Stats NZ said today. “For a third consecutive month, card spending on the long-lasting goods (durables) remained at higher levels than last year, after ... More>>

Contact: Business Drops, New Generation On Hold

New Zealand’s second-largest energy company Contact Energy (‘Contact’) released its full year financial results for the 12 months to 30 June 2020 (‘FY20’) this morning. More>>

Mining: OceanaGold Announces Receipt Of WKP Mining Permit

MELBOURNE, Australia, Aug. 6, 2020 /CNW/ - OceanaGold Corporation (TSX: OGC) (ASX: OGC) (the 'Company') is pleased to announce it has received the mining permit for Wharekirauponga ('WKP') on the North Island of New Zealand. ... More>>


Economy: COVID-19 Lockdown Has Widespread Effects On Labour Market

In the June 2020 quarter, the seasonally adjusted unemployment rate fell to 4.0 percent, down from 4.2 percent last quarter, while underutilisation rose, Stats NZ said today. More>>


NZ Post: New Research By NZ Post Shows Online Shopping Grew 105% In Alert Level 3

New research by NZ Post into how the COVID-19 response has impacted the way Kiwis shop online, shows online shopping increased 105%* when the country moved into Alert Level 3, and may have changed the way Kiwis shop permanently. Online spend peaked ... More>>


Antarctica NZ: Ice-Olation

Antarctica New Zealand is gearing up for a much reduced season on the ice this year and a very different deployment to normal! Before they head to one of the remotest places on the planet, all personnel flying south with the New Zealand programme will ... More>>


QV Valuations: July House Price Index Illustrates Market Resilience

According to the July 2020 QV House Price Index (HPI) results out today , property values recorded a marginal increase, up 0.2% over the month. This is somewhat of a turnaround from June, after the national index edged 0.2% lower. More>>


Property: Queenstown Rents Experience Biggest Drop In Seven Years

Rental prices in the Queenstown-Lakes district saw the biggest annual percentage drop in seven years after falling 28 per cent on June last year, according to the latest Trade Me Rental Price Index. Trade Me Property spokesperson Aaron Clancy said ... More>>

Seismology: The Quiet Earth

As many daily activities came to a halt during lockdown, the Earth itself became quiet, probably quieter than it has been since humans developed the technology to listen in. Seismologists have analysed datasets from more than 300 international ... More>>

RNZ: James Shaw Says Kiwibank, Not Ministers Should Decide On Investors

Climate Change Minister James Shaw says Kiwibank's decision to stop doing business with companies dealing in fossil fuels is the right one. More>>


FMA: Kiwis Confident Financial Markets Will Recover From COVID-19, Plan To Increase Investments

Despite the majority (60%) of investors experiencing losses as a result of COVID-19, the outlook on investing remains positive, according to a Financial Markets Authority (FMA) survey. Most Kiwis (71%) were optimistic that the pandemic will pass eventually ... More>>

FIRST Union: Warehouse Using Covid For Cover As Extensive Restructure Makes Everyone Worse Off

(FIRST Union comments on The Warehouse consultation and proposed restructure) 'Unfortunately the Warehouse have done the disappointing thing and used Covid-19 to justify a bunch of operational business decisions that will leave hundreds of workers without jobs ... More>>